Bicara reports Q3-2026 financial results and updates on pivotal HNSCC trial
Bicara Therapeutics reported third-quarter 2026 financial results and announced substantial enrollment in its FORTIFI-HN01 pivotal trial for head and neck cancer; interim data is expected in mid-2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed